At the Thirteenth International Kidney Cancer Symposium, Dr Laurence Albiges (Gustave Roussy, France) provides an overview of papillary renal cell carcinoma (pRCC) and management options for these patients. pRCC comprises 10–15% of renal cell carcinoma and specific therapies are not available. There are two clinically distinct types of pRCC. The more common Type 1 pRCC is associated with a mutation in the MET gene.
Year of Production: